In brief
At SupplySide Global 2026 in Las Vegas, Chinese firms Ganoherb and Changsha Huir unveiled finished‑product lines and announced plans to build U.S. processing plants, signaling a shift from raw‑material supply toward branded goods. Leaders said the U.S. market and local partnerships are key to expanding their global footprint, amid a backdrop where China supplies about 80 percent of the dietary supplement industry's raw materials.
At SupplySide Global 2026, concluded on Friday at Las Vegas’ Mandalay Bay, Chinese health‑ingredient firms demonstrated their products and manufacturing capabilities, aiming to move up the value chain with branded finished goods. The event attracted more than 1,600 exhibitors and over 20,000 industry professionals, including a record 600 Chinese companies.
Ganoherb Group, a major Chinese producer of organic reishi mushroom (lingzhi) products, showcased coffee and tea made with concentrated extracts. Li Ye, the company’s president and founder, told Xinhua :
"We plan to focus more on branded products in the U.S. market, building on China’s traditional strengths in lingzhi cultivation."
Changsha Huir Biological-tech Co., Ltd., based in Hunan Province, also highlighted its move up the value chain. The company has supplied natural extracts overseas for more than a decade and now plans to build a U.S. processing facility to manufacture finished products for global distribution. Yuan Zhi, the general manager, said :
"China’s advantages include diverse raw‑material sources and increasingly automated, energy‑efficient production equipment. The planned facility will extend our business beyond ingredient supply and create a more integrated supply chain."
The shift reflects a broader industry trend. “China supplies roughly 80 percent of the industry’s raw materials,” said Loren Israelsen, president of the United Natural Products Alliance. “Having good Chinese suppliers is fundamental to the success of the American marketplace.”
While the companies’ announcements underscore their intent to build U.S. operations, the specifics of the facility locations and partnership details remain unconfirmed as the firms navigate regulatory and market considerations.
